EAM
ELVN icon

Exome Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Exome Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.09M Sell
100,203
-119,888
-54% -$5.09M 3.14% 10
2026
Q1 		$8.63M Sell
220,091
-2,217
-1% -$61.4K 4.46% 3
2025
Q4 		$3.42M Buy
+222,308
New +$4.43M 1.64% 21
2024
Q2 		– Sell
-57,635
Closed -$1.01M – 59
2024
Q1 		$1.01M Buy
+57,635
New +$884K 0.87% 46

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Exome Asset Management's ELVN Position: Q2 2026 in Review

Exome Asset Management reduced its Enliven Therapeutics (ELVN) stake by 54% in Q2 2026, selling an estimated $5.09M and leaving 100,203 shares worth $5.09M. The position accounts for 3.14% of the portfolio, ranked #10.

Exome Asset Management first reported a position in ELVN in Q1 2024 and has held it in 4 quarters since. The position peaked at $8.63M in Q1 2026. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Exome Asset Management held 100,203 shares of Enliven Therapeutics worth $5.09M as of Q2 2026.
  • Exome Asset Management sold 119,888 Enliven Therapeutics shares in Q2 2026, an estimated $5.09M.
  • Enliven Therapeutics made up 3.14% of Exome Asset Management's portfolio in Q2 2026, its #10 holding.
  • Exome Asset Management first reported a position in Enliven Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Exome Asset Management's Enliven Therapeutics position peaked at $8.63M in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.